Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study.

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) is an FDA-approved combination therapy for HIV treatment.
• Limited real-world data exists on its effectiveness and safety, particularly in diverse populations.

Purpose of the Study:

• To evaluate real-world discontinuation rates, adverse effects, and virologic control of BIC/FTC/TAF.
• To assess the efficacy and tolerability in a predominantly African American, overweight population in the Southern US.

Main Methods:

• Retrospective, observational study design.
• Analysis of patient data from a Southern US healthcare setting.
• Evaluation of discontinuation reasons, adverse events, and viral load suppression.

Main Results:

• Optimal virologic control was observed in patients receiving BIC/FTC/TAF.
• Low discontinuation rates were reported, with only 4% discontinuing the regimen.
• Common reasons for discontinuation included rash, low platelets, loss of appetite, and insomnia.

Conclusions:

• BIC/FTC/TAF demonstrates favorable real-world effectiveness and tolerability in a predominantly African American, overweight population.
• The regimen is associated with high rates of virologic suppression and low discontinuation rates.
• Adverse effects leading to discontinuation were infrequent and manageable.